Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 11/20 | 0.72 |
| ▸ | DRD2 | P14416 | 9/20 | 0.72 |
| ▸ | HTR1A | P08908 | 5/20 | 0.53 |
| ▸ | HTR7 | P34969 | 2/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9367037 | 0.86 | DRD2 (0.69) | HTR2ADRD2HTR1AHTR7KCNH2 | |
| SCHEMBL5767056 | 0.85 | HTR2A (0.57) | HTR2ADRD2HTR1AHTR7KCNH2 | |
| SCHEMBL5766916 | 0.84 | HTR2A (0.73) | HTR2ADRD2HTR1AHTR7KCNH2 | |
| SCHEMBL6187894 | 0.83 | HTR2A (1.00) | HTR2ADRD2HTR1AHTR7KCNH2 | |
| SCHEMBL6185292 | 0.83 | HTR2A (1.00) | HTR2ADRD2HTR1AHTR7KCNH2 | |
| SCHEMBL6188693 | 0.82 | HTR2A (0.79) | HTR2ADRD2HTR1AHTR7KCNH2 | |
| SCHEMBL6187384 | 0.81 | HTR2A (0.90) | HTR2ADRD2HTR1AHTR7 | |
| SCHEMBL6751052 | 0.81 | HTR2A (0.53) | HTR2ADRD2HTR1AHTR7KCNH2 | |
| SCHEMBL6222415 | 0.80 | HTR2A (0.54) | HTR2ADRD2 | |
| SCHEMBL6743902 | 0.78 | HTR2A (0.57) | HTR2ADRD2HTR1AHTR7KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1701954-A1 | N-SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES | Warner-Lambert Company LLC (US) | 2006-09-20 | — | — | EP | disclosed |
| WO-2005066165-A1 | N-SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES | WARNER-LAMBERT COMPANY LLC (US) | 2005-07-21 | — | — | WO | disclosed |